Requirements for laboratories reporting tests for the National Cervical Screening Program (Second Edition 2019)
This document was published by the National Pathology Accreditation Advisory Council (NPAAC) whilst under the governance of the Department of Health and Aged Care. From 1 July 2021, the Australian Commission on Safety and Quality in Health Care (the Commission) assumed responsibility for coordinating the National Pathology Accreditation (NPA) Scheme and supporting the development of the pathology accreditation standards.
Requirements for laboratories reporting tests for the National Cervical Screening Program (Second Edition 2019) is currently in use.
The Commission is undergoing a review process for each of the pathology standards. To remain up to date on upcoming consultations and to provide input, please visit the pathology accreditation standards and sign up now for ongoing updates.
For enquiries about the NPA Scheme or the resources, email firstname.lastname@example.org.
The Requirements for Laboratories Reporting Tests for the National Cervical Screening Program (Second Edition 2019) set out the minimum requirements for best practice for the use of Human Papillomavirus nucleic acid testing as the primary screening method for cervical screening with reflect liquid based cytology in cases of positive oncogenic HPV types.
Testing of self-collected specimens of symptomatic women and in the post-treatment setting has also been considered.
Accessibility - We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.
Copyright - Unless stated otherwise, materials provided are covered by a Creative Commons Attribution-Non-Commercial-Share Alike (BY-NC-ND) 4.0 International License.